Search

everythinglearnresearchcommunity

for

Search:↓

User uses 1ml RU58841 with 5ml stemoxydine for scalp coverage. Wants to switch to pyrilutamide and asks about mixing it with other compounds.

A stem cell and adenosine triphosphate cocktail showed promising results in hair regrowth for male and female mice, with potential for future clinical trials. Users humorously reacted to the success in mice, expressing hope for human application.

Kintor's Pyrilutamide (KX-826) showed hair growth in Chinese Phase III trials but did not significantly outperform placebo. The treatment was safe with no major adverse reactions reported.

User discusses trying Low Level Laser Therapy (LLLT) for hair loss and its high cost. Another user shares their experience combining micro needling, minoxidil, and LLLT, seeing positive results after 2 months.

The user is considering switching from pyrilutamide to 0.025% topical finasteride due to concerns about effectiveness and past side effects from a scalp elixir. They aim to maintain hair until new treatments like breezula or GT00029 become available.

The user has been using Minoxidil and finasteride with success and is now trying Dualgen-5R with retinoic acid but without finasteride, along with microneedling. They plan to share results in 5-6 months.

The conversation discusses the potential of a new hair loss treatment, GT20029, which targets androgen receptors in the scalp and is in phase 1 trials in China. Users express hope that this treatment will be more effective than current options like Minoxidil and Finasteride.

Transplanting mice skin to humans is not feasible due to immune rejection, but some suggest genetic modification or immune suppression could make it possible. Xenograft hair transplants are discouraged.

A user is considering using verteporfin with microneedling, oral/topical minoxidil, and RU58841 to treat hair loss. They seek advice on dosage and application methods.

A 33-year-old male is thrilled with his hair transplant results one year post-procedure, having used 1 mg finasteride and 2.5 mg oral minoxidil daily, which significantly improved his hair density. The transplanted hair is expected to be permanent, but continued use of finasteride is recommended to maintain surrounding native hair.

The post and conversation discuss Verteporfin's potential as a hair loss treatment. It's shown promise in regrowing hair after transplants and might be effective with microneedling.

The conversation discusses affordable low-level light therapy (LLLT) products for hair loss, with users debating the effectiveness of red LEDs versus lasers. The original poster is already using finasteride, minoxidil, ketoconazole, and microneedling, and is seeking budget-friendly LLLT options to add to their regimen.

User had minor hair transplant in 2020, used Fin since 2008, Min since 2014, and added microneedling in 2022. Routine was irregular with no severe effects.

The efficacy of degrading the androgen receptor through dermal application in DP cells, a delivery system for topical drugs that involves dissolving microneedles, and rosemary oil as an alternative anti-androgen.

A 26-year-old male considering a hair transplant is using topical finasteride and minoxidil, planning to start feminizing hormone replacement therapy (HRT) with estrogen and spironolactone. Many suggest waiting to see the effects of HRT, which may significantly regrow hair, before deciding on a transplant, and recommend adding microneedling and possibly switching to oral treatments for better results.

A trans woman is using finasteride, minoxidil, microneedling, and HRT to address hair loss, with noticeable improvement in hairline shape and presence of vellus hairs. She is considering hair transplants if these treatments don't yield desired results within a year or two.

Dr. Bloxham's 9-month update on FUT scar revision with Verteporfin shows promising results. Excitement is high for FUE, which appears highly effective based on Dr. Barghouthi's findings.

The conversation discusses concerns about Dr. Rassman's topical Finasteride, specifically whether it is liposomal or glycol-based. Dr. Rassman insists on providing the correct liposomal formulation and urges patients to contact him if they receive the wrong product.

A user diagnosed with Alopecia Areata started using Litfulo (ritlecitinib), kenalog shots, and mometasone furoate 0.1%. They shaved their head and are seeking others' experiences with Litfulo.

The user halted hair loss using 0.01% topical liposomal finasteride daily, with no side effects or regrowth, and recently added 5% minoxidil and low-level laser therapy. They recommend this conservative approach for those hesitant about finasteride.

The conversation discusses positive initial trial results for GT20029, a topical compound for hair loss that degrades androgen receptors, potentially requiring only weekly application. Participants express hope for this treatment to be more effective and convenient than current options like Minoxidil, Finasteride, and RU58841.

Verteporfin is being discussed for its potential to regrow hair and heal scars, possibly aiding hair transplants or replacing them. Some users are skeptical about its effectiveness, while others suggest combining it with microneedling for better results.

The conversation is about the effectiveness of low-level laser therapy (LLLT) caps for hair regrowth. One user suggests saving money, implying LLLT caps may not be beneficial.

User discusses verteporfin for hair regrowth through "super microneedling" and preventing scarring. They mention a case of an old man regrowing hair after a head injury and suggest verteporfin could recreate this result.

A hair restoration case involved injecting four different doses of Verteporfin into the mid scalp and using Scalp MicroPigmentation (SMP) around the extraction areas. Photos were taken and an update will be shared soon.

ET-02 showed significant hair growth in five weeks, outperforming minoxidil, with a non-hormonal mechanism that avoids side effects of treatments like finasteride. A phase 2 trial is planned to further assess ET-02's efficacy and safety.

Kintor Pharma finished enrolling and dosing participants in a Phase I trial for a hair loss treatment called AR-PROTAC (GT20029). The effectiveness of another drug, pyrilutamide (KX-826), for hair loss will be clearer after a Phase 2 trial expected to complete in January 2023.

Hair loss treatment with latanoprost, minoxidil, and biotin showed progress. Latanoprost, a glaucoma drug, stimulates anagen phase and increases conversion of vellus hair to terminal hair.

A case study that suggests verteporfin may be able to help regrow donor hairs after FUE extraction, and the potential implications of this result. Treatments discussed include Minoxidil, Finasteride, and RU58841.

The conversation is about the availability of WINLEVI, a hair loss treatment, and the possibility of getting it compounded. The user is seeking information on when they can obtain the treatment.